Full Year 2018 Immunovia AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the Immunovia Full Year Report for 2018. Today, I'm pleased to present Mats Grahn, the CEO. (Operator Instructions) Mats, please begin.
()-
Thank you, and welcome to the full year report 2019. For the agenda today, I will comment on the main activities for 2018 and onwards, and that is the PanCan-d commercialization project and the main aspects of that, of course. We will comment on the IMMray platform opportunities and the pipeline, the NASDAQ listing and the increased focus on IR and our capacity there, what we need for 2019. And then also of course, on the finances.
So let me begin with PanCan-d commercialization, which is obviously our main focus. And there are several key elements of these activities. As we have announced in 2018, the production and chemical labs in the main office in Lund has been increased in capacity and put in place, which is crucial. The capacity is imitating of the product. It reached about 120,000 tests and we have 2 [more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
